Markets ABBV

AbbVie Trims FY26 Adj. EPS Outlook - Update

July 31, 2026 — 08:22 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - While reporting financial results for the second quarter on Friday, biopharmaceutical company AbbVie, Inc. (ABBV) trimmed its adjusted earnings guidance for the full-year 2026.

For fiscal 2026, AbbVie now projects adjusted earnings in a range of $13.87 to $14.07 per share, down from the prior forecast range of $13.91 to $14.11 per share.

The company said the guidance include the impact of the proposed Apogee Therapeutics acquisition, which is expected to be $0.14 dilutive in 2026, based upon an anticipated close in the third quarter of this year. This dilution is partially offset by $0.10 of overperformance.

It also includes an unfavorable impact of $0.58 per share related to acquired IPR&D and milestones expense incurred year-to-date through the second quarter 2026.

In Friday's pre-market trading, ABBV is trading on the NYSE at $248.00, down $9.51 or 3.69 percent.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

RTTNews
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.
More articles by this source

Tags

Markets
Stocks Mentioned
ABBV

Latest Articles
Data is currently not available